Search - tctmd.com

Displaying 361 - 380 of 485

Sort: Relevancy | Date

News Daily News

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

L.A. McKeown

August 24, 2016

News Daily News

Medtronic Warns of Vascular Trauma, Some Resulting in Death, With CoreValve’s EnVeo R Delivery Catheter

Michael O'Riordan

August 18, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Daily News

Antithrombotic Cocktail Fails to Provide Benefit, Increases Bleeding in A-Fib Patients Undergoing TAVR

Yael L. Maxwell

August 16, 2016

News Daily News

New-Onset A-Fib, Chronic Kidney Disease Are Risk Factors For Stroke After TAVR, Meta-Analysis Shows

Yael L. Maxwell

August 10, 2016

News Daily News

CMR Confirms Link Between Moderate Aortic Regurgitation Post-TAVR and Poor Outcomes, Mortality

Yael L. Maxwell

August 05, 2016

News Daily News

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Todd Neale

August 01, 2016

News Daily News

Blood Test May Be Useful for Detecting Aortic Regurgitation During TAVR

L.A. McKeown

July 27, 2016

News Daily News

Simple Risk-Scoring System Predicts Mortality After TAVR

Michael O'Riordan

July 25, 2016

News Daily News

Sapien 3: Results for High-Risk, Inoperable TAVR Patients Now in Print

Yael L. Maxwell

July 12, 2016

News Opinion Conversations in Cardiology

Conversations in Cardiology: In the United States, Should TAVR Be Offered to a Low-Risk Patient?

July 11, 2016

News Daily News

TAVR for Bicuspid Aortic Valve Stenosis Feasible, but Associated With Higher Rate of Permanent Pacemaker Implantation

Michael O'Riordan

July 05, 2016

News Conference News TVT 2016

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Michael O'Riordan

June 20, 2016

News Conference News TVT 2016

Valve Degeneration Data Dearth Spurs Calls for Universal Definitions and Clinical Guidance

Shelley Wood

June 20, 2016

News Conference News TVT 2016

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

Michael O'Riordan

June 18, 2016

News Conference News TVT 2016

What TAVR Needs Next . . . and What It’s Getting

Shelley Wood

June 17, 2016

News Features

Digesting the Valve Degeneration Data: One Month Later, Reactions From TAVR Experts Range From ‘Disturbed’ to Indifferent

Caitlin E. Cox

June 17, 2016

Presentation TVT 2016

Study Design for the PARTNER 3 Low-Risk Trial

Presenter: Martin B. Leon

June 16, 2016

Presentation TVT 2016

Study Design for the EVOLUT R Low-Risk Trial

Presenter: Jeffrey J. Popma

June 16, 2016

Presentation TVT 2016

The Relentless Journey of TAVR to Lower-Risk Patients: Are We There Yet?

Presenter: Martin B. Leon

June 16, 2016

Advertisement

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

Medtronic Warns of Vascular Trauma, Some Resulting in Death, With CoreValve’s EnVeo R Delivery Catheter

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Antithrombotic Cocktail Fails to Provide Benefit, Increases Bleeding in A-Fib Patients Undergoing TAVR

New-Onset A-Fib, Chronic Kidney Disease Are Risk Factors For Stroke After TAVR, Meta-Analysis Shows

CMR Confirms Link Between Moderate Aortic Regurgitation Post-TAVR and Poor Outcomes, Mortality

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Blood Test May Be Useful for Detecting Aortic Regurgitation During TAVR

Simple Risk-Scoring System Predicts Mortality After TAVR

Sapien 3: Results for High-Risk, Inoperable TAVR Patients Now in Print

Conversations in Cardiology: In the United States, Should TAVR Be Offered to a Low-Risk Patient?

TAVR for Bicuspid Aortic Valve Stenosis Feasible, but Associated With Higher Rate of Permanent Pacemaker Implantation

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Valve Degeneration Data Dearth Spurs Calls for Universal Definitions and Clinical Guidance

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

What TAVR Needs Next . . . and What It’s Getting

Digesting the Valve Degeneration Data: One Month Later, Reactions From TAVR Experts Range From ‘Disturbed’ to Indifferent

Study Design for the PARTNER 3 Low-Risk Trial

Study Design for the EVOLUT R Low-Risk Trial

The Relentless Journey of TAVR to Lower-Risk Patients: Are We There Yet?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content